Heart failure in hypertension: Prevention and treatment

Drugs

Volumn 72, Issue 10, 2012, Pages 1373-1398

  Georgiopoulou, Vasiliki V ^a   Kalogeropoulos, Andreas P ^a   Butler, Javed ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

ACE inhibitors; Aldosterone antagonists; Aliskiren; Amlodipine; Atenolol; Bumetanide; Calcium channel antagonists; Candesartan cilexetil; Captopril; Chlortalidone; Diuretics; Enalapril; Furosemide; Heart failure; Hydralazineisosorbide dinitrate; Hydrochlorothiazide; Hypertension; Intervention; Irbesartan; Lisinopril; Loop diuretics; Losartan; Nebivolol; Ramipril; Telmisartan; Thiazide diuretics; Torasemide

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; CHLOROTHIAZIDE; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LISINOPRIL; NEBIVOLOL; RAMIPRIL; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIETARY INTAKE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREHYPERTENSION; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM INTAKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; DIET, REDUCING; EXERCISE; HEART FAILURE; HUMANS; HYPERTENSION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84863210330     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11631100-000000000-00000     Document Type: Review

References (235)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-52 (Pubitemid 37553153)
2. Robinson SC. Range of normal blood pressure: a statistical and clinical study of 11 383 persons. Arch Intern Med 1939; 64: 409-44
3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360 (9349): 1903-13 (Pubitemid 35472129)
4. Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001 Nov 17; 358 (9294): 1682-6 (Pubitemid 33124327)
5. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002 Feb 27; 287 (8): 1003-10 (Pubitemid 34252058)
6. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005 Jul 27; 294 (4): 466-72 (Pubitemid 41124179)
7. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 2004 Oct 25; 164 (19): 2126-34 (Pubitemid 39410802)
8. Ogunniyi MO, Croft JB, Greenlund KJ, et al. Racial/ethnic differences in microalbuminuria among adults with prehypertension and hypertension: National Health and Nutrition Examination Survey (NHANES), 1999-2006. Am J Hypertens 2010 Aug; 23 (8): 859-64
9. Nieto FJ, Alonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia: the Atherosclerosis Risk in Communities study. Arch Intern Med 1995 Apr 10; 155 (7): 677-84
10. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension 2000 Nov; 36 (5): 780-9
11. Wyatt SB, Akylbekova EL, Wofford MR, et al. Prevalence, awareness, treatment, and control of hypertension in the Jackson Heart Study. Hypertension 2008 Mar; 51 (3): 650-6 (Pubitemid 351301516)
12. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan 15-21; 365 (9455): 217-23 (Pubitemid 40138015)
13. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003 May 14; 289 (18): 2363-9 (Pubitemid 37430168)
14. Gu D, Reynolds K, Wu X, et al. Prevalence, awareness, treatment, and control of hypertension in china. Hypertension 2002 Dec; 40 (6): 920-7 (Pubitemid 35434917)
15. Reynolds K, GuD, Muntner P, et al. Geographic variations in the prevalence, awareness, treatment and control of hypertension in China. J Hypertens 2003 Jul; 21 (7): 1273-81
16. Gupta PC, Gupta R, Pednekar MS. Hypertension prevalence and blood pressure trends in 88 653 subjects in Mumbai, India. J Hum Hypertens 2004 Dec; 18 (12): 907-10 (Pubitemid 39600148)
17. Sekikawa A, Hayakawa T. Prevalence of hypertension, its awareness and control in adult population in Japan. J Hum Hypertens 2004 Dec; 18 (12): 911-2 (Pubitemid 39600149)
18. Martiniuk AL, Lee CM, Lawes CM, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens 2007 Jan; 25 (1): 73-9 (Pubitemid 44885666)
19. Meehan KA, Bankoski AJ, Tejan E, et al. Hypertension in Bo, Sierra Leone. Ethn Dis 2011 Spring; 21 (2): 237-42
20. Twagirumukiza M, De Bacquer D, Kips JG, et al. Current and projected prevalence of arterial hypertension in sub-Saharan Africa by sex, age and habitat: an estimate from population studies. J Hypertens 2011 Jul; 29 (7): 1243-52
21. Steyn K, Bradshaw D, Norman R, et al. Determinants and treatment of hypertension in South Africans: the first Demographic and Health Survey. S Afr Med J 2008 May; 98 (5): 376-80 (Pubitemid 351781086)
22. Ibrahim MM. Epidemiology of hypertension in Egypt. Saudi J Kidney Dis Transpl 1999 Jul-Sep; 10 (3): 352-6
23. Khedda S, Chibane A, Temmar M, et al. Hypertension in Algeria: results of the national survey, 2004 [online]. Available from URL: http://www.ehs-egypt. net/pdf/panselim. pdf [Accessed 2012 Oct 2]
24. Ben Romdhane H, Ben Ali S, Skhiri H, et al. Hypertension among Tunisian adults: results of the TAHINA project. Hypertens Res 2012 Mar; 35 (3): 341-7
25. Rubinstein A, Alcocer L, Chagas A. High blood pressure in Latin America: a call to action. Ther Adv Cardiovasc Dis 2009 Aug; 3 (4): 259-85
26. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995 Jul; 26 (1): 60-9
27. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008 Nov; 52 (5): 818-27
28. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. Epub 2011 Dec 15
29. Ostchega Y, Dillon CF, Hughes JP, et al. Trends in hypertension prevalence, awareness, treatment, and control in older US adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007 Jul; 55 (7): 1056-65 (Pubitemid 47024610)
30. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004 Oct; 44 (4): 398-404 (Pubitemid 39281486)
31. Ahluwalia IB, Mack KA, Murphy W, et al. State-specific prevalence of selected chronic disease-related characteristics: Behavioral Risk Factor Surveillance System, 2001. MMWR Surveill Summ 2003 Aug 22; 52 (8): 1-80
32. Aslam F, Haque A, Agostini JV, et al. Hypertension prevalence and prescribing trends in older US adults: 1999-2004. J Clin Hypertens (Greenwich) 2010 Feb 1; 12 (2): 75-81
33. Arnett DK, McGovern PG, Jacobs Jr DR, et al. Fifteenyear trends in cardiovascular risk factors (1980-1982 through 1995-1997): the Minnesota Heart Survey. Am J Epidemiol 2002 Nov 15; 156 (10): 929-35 (Pubitemid 35304073)
34. Cornoni-Huntley J, LaCroix AZ, Havlik RJ. Race and sex differentials in the impact of hypertension in the United States: the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Intern Med 1989 Apr; 149 (4): 780-8 (Pubitemid 19132997)
35. Diez Roux AV, Chambless L, Merkin SS, et al. Socioeconomic disadvantage and change in blood pressure associated with aging. Circulation 2002 Aug 6; 106 (6): 703-10 (Pubitemid 34851930)
36. Dyer AR, Liu K, Walsh M, et al. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. Coronary Artery Risk Development in (Young) Adults. J Hum Hypertens 1999 Jan; 13 (1): 13-21 (Pubitemid 29042140)
37. Vargas CM, Ingram DD, Gillum RF. Incidence of hypertension and educational attainment: the NHANES I epidemiologic follow up study. First National Health and Nutrition Examination Survey. Am J Epidemiol 2000 Aug 1; 152 (3): 272-8
38. Dannenberg AL, Garrison RJ, Kannel WB. Incidence of hypertension in the Framingham Study. Am J Public Health 1988 Jun; 78 (6): 676-9
39. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001 Mar; 37 (3): 869-74 (Pubitemid 32221606)
40. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001 Mar 6; 103 (9): 1245-9 (Pubitemid 32221347)
41. Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med 2008 Oct 27; 168 (19): 2138-45
42. Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, et al. Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. Arch Intern Med 2009 Apr 13; 169 (7): 708-15
43. Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008 Apr 1; 101 (7): 1016-22
44. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005 Mar-Apr; 47 (5): 320-32 (Pubitemid 40884561)
45. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995 Dec; 26 (7): 1565-74
46. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004 Feb 4; 43 (3): 317-27 (Pubitemid 38167688)
47. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007 Aug 21; 50 (8): 768-77 (Pubitemid 47243795)
48. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006 Jul 20; 355 (3): 251-9 (Pubitemid 44079340)
49. Hobbs FD, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002 Dec; 23 (23): 1867-76 (Pubitemid 35398056)
50. Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002 Mar; 87 (3): 235-41 (Pubitemid 34177677)
51. Oghlakian GO, Sipahi I, Fang JC. Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? Mayo Clin Proc 2011 Jun; 86 (6): 531-9
52. Das A, Abraham S, Deswal A. Advances in the treatment of heart failure with a preserved ejection fraction. Curr Opin Cardiol 2008 May; 23 (3): 233-40 (Pubitemid 351489326)
53. Shin DD, Brandimarte F, De Luca L, et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007 Jan 22; 99 (2A): 4A-23A
54. Eriksson H, Svardsudd K, Larsson B, et al. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J 1989 Jul; 10 (7): 647-56 (Pubitemid 19202160)
55. Haider AW, Larson MG, Franklin SS, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003 Jan 7; 138 (1): 10-6 (Pubitemid 36232089)
56. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996 May 22-29; 275 (20): 1557-62 (Pubitemid 26154241)
57. Aronow WS, Ahn C. Incidence of heart failure in 2737 older persons with and without diabetes mellitus. Chest 1999 Mar; 115 (3): 867-8 (Pubitemid 29129974)
58. Ekundayo OJ, Allman RM, Sanders PW, et al. Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study. Hypertension 2009 Mar; 53 (3): 458-65
59. Demirovic J, Prineas R, Rudolph M. Epidemiology of congestive heart failure in three ethnic groups. Congest Heart Fail 2001 Mar-Apr; 7 (2): 93-6 (Pubitemid 32927267)
60. Kannel WB, D'Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med 1999 Jun 14; 159 (11): 1197-204 (Pubitemid 29269859)
61. Bibbins-Domingo K, Lin F, Vittinghoff E, et al. Predictors of heart failure among women with coronary disease. Circulation 2004 Sep 14; 110 (11): 1424-30 (Pubitemid 39263737)
62. Hsia J, Margolis KL, Eaton CB, et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 2007 Feb 20; 115 (7): 855-60 (Pubitemid 46294726)
63. Britton KA, Gaziano JM, Djousse L. Normal systolic blood pressure and risk of heart failure in US male physicians. Eur J Heart Fail 2009 Dec; 11 (12): 1129-34
64. Vasan RS, Larson MG, Leip EP, et al. Impact of highnormal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001 Nov 1; 345 (18): 1291-7
65. Butler J, Kalogeropoulos AP, Georgiopoulou VV, et al. Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study. Heart 2011 Aug; 97 (16): 1304-11
66. Chae CU, Pfeffer MA, Glynn RJ, et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999 Feb 17; 281 (7): 634-9 (Pubitemid 29098064)
67. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the National Heart, Lung, and Blood Institute. Circulation 2009 Jun 23; 119 (24): 3070-7
68. Butler J, Kalogeropoulos A, Georgiopoulou V, et al. Incident heart failure prediction in the elderly: the Health ABC heart failure score. Circ Heart Fail 2008 July 1; 1 (2): 125-33
69. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002 Dec 10; 106 (24): 3068-72 (Pubitemid 35440290)
70. Georgiopoulou VV, Kalogeropoulos AP, Butler J. Dilemmas of blood pressure management for heart failure prevention. Circ Heart Fail 2011 Jul; 4 (4): 528-33
71. Drukteinis JS, Roman MJ, Fabsitz RR, et al. Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: the Strong Heart Study. Circulation 2007 Jan 16; 115 (2): 221-7 (Pubitemid 46105721)
72. Weber KT, Brilla CG, Campbell SE, et al. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press 1992 Aug; 1 (2): 75-85
73. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med 1996 Sep 9; 156 (16): 1789-96
74. Marcus ML, Harrison DG, Chilian WM, et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 1987 Jan; 75 (1 Pt 2): I19-25
75. Brush Jr JE, Cannon 3rd RO, Schenke WH, et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 1988 Nov 17; 319 (20): 1302-7 (Pubitemid 19003391)
76. Nolan SE, Mannisi JA, Bush DE, et al. Increased afterload aggravates infarct expansion after acute myocardial infarction. J Am Coll Cardiol 1988 Nov; 12 (5): 1318-25
77. Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure: treatment strategies. Heart Fail Rev 2008 Sep; 13 (3): 367-75
78. Wright JW, Harding JW. The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory. Prog Neurobiol 2004 Mar; 72 (4): 263-93 (Pubitemid 38609580)
79. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005 Sep 20; 112 (12): e154-235
80. Wang TJ, Levy D, Benjamin EJ, et al. The epidemiology of 'asymptomatic' left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003 Jun 3; 138 (11): 907-16
81. Davies M, Hobbs F, Davis R, et al. Prevalence of leftventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001 Aug 11; 358 (9280): 439-44 (Pubitemid 32769849)
82. Redfield MM, Jacobsen SJ, Burnett Jr JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003 Jan 8; 289 (2): 194-202 (Pubitemid 36068707)
83. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997 Sep 20; 350 (9081): 829-33 (Pubitemid 27404343)
84. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003 Aug 26; 108 (8): 977-82 (Pubitemid 37048228)
85. Verdecchia P, Angeli F, Gattobigio R, et al. Asymptomatic left ventricular systolic dysfunction in essential hyperten-sion: prevalence, determinants, and prognostic value. Hypertension 2005 Mar; 45 (3): 412-8 (Pubitemid 40326250)
86. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992 Sep 3; 327 (10): 669-77
87. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995 Dec 21; 333 (25): 1670-6 (Pubitemid 26001955)
88. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003 May 31; 361 (9372): 1843-8 (Pubitemid 36645177)
89. Dries DL, Strong MH, Cooper RS, et al. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in Black and White patients. J Am Coll Cardiol 2002 Jul 17; 40 (2): 311-7 (Pubitemid 34756293)
90. Exner DV, Dries DL, Waclawiw MA, et al. Betaadrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999 Mar 15; 33 (4): 916-23
91. No authors listed. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997 Feb 8; 349 (9049): 375-80
92. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensinconverting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. SAVE Investigators. J Am Coll Cardiol 1997 Feb; 29 (2): 229-36 (Pubitemid 27059948)
93. Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo substudy. Circulation 2004 Jan 20; 109 (2): 201-6 (Pubitemid 38114140)
94. Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 2001 Dec 1; 88 (11): 1298-300 (Pubitemid 33132100)
95. Chen YT, Vaccarino V, Williams CS, et al. Risk factors for heart failure in the elderly: a prospective communitybased study. Am J Med 1999 Jun; 106 (6): 605-12 (Pubitemid 29279295)
96. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000 May; 35 (6): 1628-37 (Pubitemid 30307510)
97. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001 Apr 9; 161 (7): 996-1002 (Pubitemid 32295654)
98. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men: morbidity, risk factors and prognosis. J Intern Med 2001 Mar; 249 (3): 253-61 (Pubitemid 32417788)
99. Carr AA, Kowey PR, Devereux RB, et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005 Dec 1; 96 (11): 1530-6 (Pubitemid 41690173)
100. Kalogeropoulos A, Psaty BM, Vasan RS, et al. Validation of the health ABC heart failure model for incident heart failure risk prediction: the Cardiovascular Health Study. Circ Heart Fail 2010 Jul; 3 (4): 495-502
101. Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005 Jan 29-Feb 4; 365 (9457): 434-41 (Pubitemid 40179232)
102. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA1986Nov 28; 256 (20): 2823-8 (Pubitemid 17178359)
103. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet 1986 Oct 25; 2 (8513): 933-6 (Pubitemid 17197838)
104. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, et al. Out-of-hospital cardiac arrest: the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 2003 Jul; 24 (13): 1204-9 (Pubitemid 36834636)
105. Myerburg RJ, Mitrani R, Interian Jr A, et al. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation 1998 Apr 21; 97 (15): 1514-21 (Pubitemid 28191308)
106. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 Jul 13; 110 (2): 227-39 (Pubitemid 38924592)
107. Ferrucci L, Furberg CD, Penninx BW, et al. Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation 2001 Oct 16; 104 (16): 1923-6 (Pubitemid 32983235)
108. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 May 16; 285 (19): 2486-97
109. Giles TD, Berk BC, Black HR, et al. Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) 2005 Sep; 7 (9): 505-12
110. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25 (6): 1105-87 (Pubitemid 46924065)
111. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998 May 12; 97 (18): 1837-47 (Pubitemid 28213628)
112. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002 Oct 16; 288 (15): 1882-8 (Pubitemid 35168144)
113. Falkner B, Gidding SS, Portman R, et al. Blood pressure variability and classification of prehypertension and hypertension in adolescence. Pediatrics 2008 Aug; 122 (2): 238-42
114. Geleijnse JM, Kok FJ, Grobbee DE. Impact of dietary and lifestyle factors on the prevalence of hypertension in Western populations. Eur J Public Health 2004 Sep; 14 (3): 235-9 (Pubitemid 39093616)
115. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003 Nov; 42 (5): 878-84 (Pubitemid 37413724)
116. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001 Jan 2; 134 (1): 1-11 (Pubitemid 32037337)
117. Blair SN, Goodyear NN, Gibbons LW, et al. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA 1984 Jul 27; 252 (4): 487-90 (Pubitemid 14088099)
118. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. N Engl J Med 1997 Apr 17; 336 (16): 1117-24
119. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASHSodium Collaborative Research Group. N Engl J Med 2001 Jan 4; 344 (1): 3-10 (Pubitemid 32064838)
120. No authors listed. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997 Mar 24; 157 (6): 657-67
121. Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001 Mar 12; 161 (5): 685-93 (Pubitemid 32200220)
122. Frohlich ED, Chien Y, Sesoko S, et al. Relationship between dietary sodium intake, hemodynamics, and cardiac mass in SHR and WKY rats. Am J Physiol 1993 Jan; 264 (1 Pt 2): R30-4 (Pubitemid 23053523)
123. de Simone G, Devereux RB, Camargo MJ, et al. Influence of sodium intake on in vivo left ventricular anatomy in experimental renovascular hypertension. Am J Physiol 1993 Jun; 264 (6 Pt 2): H2103-10 (Pubitemid 23205982)
124. de Simone G, Devereux RB, Camargo MJ, et al. Reduction of development of left ventricular hypertrophy in saltloaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am J Hypertens 1996 Mar; 9 (3): 216-22 (Pubitemid 26121272)
125. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003 Apr 23-30; 289 (16): 2083-93 (Pubitemid 37430210)
126. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled Trial of Nonpharmacologic Interventions in the Elderly (TONE). TONE Collaborative Research Group. JAMA 1998 Mar 18; 279 (11): 839-46 (Pubitemid 28185548)
127. Elmer PJ, Obarzanek E, Vollmer WM, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006 Apr 4; 144 (7): 485-95 (Pubitemid 46780671)
128. Hyman DJ, Pavlik VN, Taylor WC, et al. Simultaneous vs sequential counseling for multiple behavior change. Arch Intern Med 2007 Jun 11; 167 (11): 1152-8 (Pubitemid 46919817)
129. Frisoli TM, Schmieder RE, Grodzicki T, et al. Beyond salt: lifestyle modifications and blood pressure. Eur Heart J 2011 Dec; 32 (24): 3081-7
130. Fuchs FD. Prehypertension: the rationale for early drug therapy. Cardiovasc Ther 2010 Dec; 28 (6): 339-43
131. Chobanian AV. Prehypertension revisited. Hypertension 2006 Nov; 48 (5): 812-4 (Pubitemid 44610983)
132. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006 Apr 20; 354 (16): 1685-97
133. Luders S, Schrader J, Berger J, et al. The PHARAO study: prevention of hypertension with the angiotensinconverting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008 Jul; 26 (7): 1487-96
134. Skov K, Eiskjaer H, Hansen HE, et al. Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker. Hypertension 2007 Jul; 50 (1): 89-95 (Pubitemid 46986015)
135. No authors listed. Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114mm Hg. JAMA 1970 Aug 17; 213 (7): 1143-52
136. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEPCooperative Research Group. JAMA 1997 Jul 16; 278 (3): 212-6 (Pubitemid 27339586)
137. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342 (3): 145-53
138. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008 May 1; 358 (18): 1887-98 (Pubitemid 351620109)
139. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993 Mar 8; 153 (5): 578-81 (Pubitemid 23072387)
140. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996 Apr; 27 (5): 1214-8 (Pubitemid 26117716)
141. Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J 2009 Mar; 30 (6): 679-88
142. Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009 Aug 15; 374 (9689): 525-33
143. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 Apr 29; 362 (17): 1575-85
144. No authors listed. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 Sep 12; 317 (7160): 703-13
145. McNair A, Rasmussen S, Nielsen PE, et al. The antihypertensive effect of prazosin on mild to moderate hypertension, changes in plasma volume, extracellular volume and glomerular filtration rate. Acta Med Scand 1980; 207 (5): 413-6 (Pubitemid 10117172)
146. Wilner KD, Ziegler MG. Effects of alpha 1 inhibition on renal blood flow and sympathetic nervous activity in systemic hypertension. Am J Cardiol 1987 May 29; 59 (14): 82G-6G (Pubitemid 17085550)
147. Davis BR, Piller LB, Cutler JA, et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2006 May 9; 113 (18): 2201-10
148. Staessen JA, Fagard R, Thijs L, et al. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997 Sep 13; 350 (9080): 757-64 (Pubitemid 27387202)
149. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998 Dec; 16 (12 Pt 1): 1823-9 (Pubitemid 28548522)
150. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep 20; 345 (12): 861-9
151. Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005 Dec; 23 (12): 2157-72 (Pubitemid 41666745)
152. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: a randomised controlled trial. Lancet 2008 Sep 27; 372 (9644): 1174-83
153. Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med 2011 Mar 14; 171 (5): 384-94
154. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999 Nov 20; 354 (9192): 1751-6
155. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000 Jul 29; 356 (9227): 366-72 (Pubitemid 30487492)
156. No authors listed. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000 Apr 19; 283 (15): 1967-75
157. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288 (23): 2981-97
158. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003 Apr 23-30; 289 (16): 2073-82 (Pubitemid 37430209)
159. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003 Feb 13; 348 (7): 583-92 (Pubitemid 36204952)
160. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995 Feb 1; 91 (3): 698-706
161. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000 Oct; 18 (10): 1465-75
162. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of singledrug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997 Apr 15; 95 (8): 2007-14 (Pubitemid 27184266)
163. DorschMP,Gillespie BW, Erickson SR, et al.Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011 Apr; 57 (4): 689-94
164. Leren P, Helgeland A. Oslo Hypertension Study. Drugs 1986; 31 Suppl. 1: 41-5 (Pubitemid 16118839)
165. No authors listed. The Australian therapeutic trial in mild hypertension: report by the Management Committee. Lancet 1980 Jun 14; 1 (8181): 1261-7
166. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008 Dec 4; 359 (23): 2417-28
167. Ernst ME, Neaton JD, Grimm Jr RH, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension 2011 Dec; 58 (6): 1001-7
168. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004 Jan; 43 (1): 4-9 (Pubitemid 38031903)
169. Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension 2010 Sep; 56 (3): 463-70
170. Klingbeil AU, Schneider M, Martus P, et al. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension. Am JMed 2003 Jul; 115 (1): 41-6 (Pubitemid 36831120)
171. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a metaanalysis of randomized double-blind studies. JAMA 1996 May 15; 275 (19): 1507-13 (Pubitemid 26140765)
172. Fagard RH, Celis H, Thijs L, et al. Regression of left ventricular mass by antihypertensive treatment: a metaanalysis of randomized comparative studies. Hypertension 2009 Nov; 54 (5): 1084-91
173. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001 Jun; 19 (6): 1167-76 (Pubitemid 32493652)
174. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 995-1003 (Pubitemid 34286536)
175. Cuspidi C, Muiesan ML, Valagussa L, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002 Nov; 20 (11): 2293-300 (Pubitemid 35388249)
176. Barrios V, Escobar C, Calderon A, et al. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J Renin Angiotensin Aldosterone Syst 2006 Dec; 7 (4): 236-42 (Pubitemid 46380775)
177. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002 Jan 24; 89 (2A): 18A-25A; discussion A-6A
178. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10; 358 (15): 1547-59 (Pubitemid 351522739)
179. Verdecchia P, Sleight P, Mancia G, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009 Oct 6; 120 (14): 1380-9
180. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362 (9395): 1527-35 (Pubitemid 37410190)
181. Angeli F, Verdecchia P, Reboldi GP, et al. Meta-analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. Am J Cardiol 2004 Jan 15; 93 (2): 240-3 (Pubitemid 38058743)
182. Angeli F, Reboldi G, Verdecchia P. Modern treatment of patients at risk: still a HOPE for ACE inhibitors? Expert Opin Pharmacother 2011 Apr; 12 (6): 839-43
183. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004 Nov 11; 351 (20): 2058-68
184. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992; 54: 227-41
185. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009 Feb 3; 119 (4): 530-7
186. Solomon SD, Shin SH, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J 2011 May; 32 (10): 1227-34
187. Novartis Pharmaceuticals Corporation. Important drug warning. 2012 [online]. Available from URL: http://www.pharma.us.novartis.com/assets/pdf/ Tekturna-Quo-Site-for-Professionals.pdf [Accessed 2012 Feb 20]
188. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 Oct 29-Nov 4; 366 (9496): 1545-53 (Pubitemid 41540112)
189. Bangalore S, Messerli FH, Kostis JB, et al. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007 Aug 14; 50 (7): 563-72 (Pubitemid 47202065)
190. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665
191. Bangalore S, Wild D, Parkar S, et al. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 2008 Sep 23; 52 (13): 1062-72
192. Caglar N, Dincer I. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial. Eur Rev Med Pharmacol Sci 2011 Dec; 15 (12): 1359-68
193. Chen N, Zhou M, Yang M, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev 2010; (8): CD003654
194. Webb AJ, Fischer U, Mehta Z, et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010 Mar 13; 375 (9718): 906-15
195. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 2011 Mar 2; 305 (9): 913-22
196. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006 Jul 20; 355 (3): 260-9 (Pubitemid 44088349)
197. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2008 Feb; 29 (3): 339-47 (Pubitemid 351197754)
198. Lenzen MJ, Scholte op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004 Jul; 25 (14): 1214-20 (Pubitemid 38891571)
199. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010 Feb 9; 55 (6): 526-37
200. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995 Oct; 13 (10): 1091-5
201. Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am J Hypertens 1998 Nov; 11 (11 Pt 1): 1394-404 (Pubitemid 28541059)
202. No authors listed. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987 Jun 4; 316 (23): 1429-35
203. No authors listed. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991 Aug 1; 325 (5): 293-302
204. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002 Oct 16; 40 (8): 1414-21 (Pubitemid 35192865)
205. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003 Sep 6; 362 (9386): 772-6 (Pubitemid 37093917)
206. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003 Sep 6; 362 (9386): 767-71 (Pubitemid 37093916)
207. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 Dec 6; 345 (23): 1667-75 (Pubitemid 33126822)
208. Kuenzli A, Bucher HC, Anand I, et al. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS ONE 2010; 5 (4): e9946
209. Mehta PA, McDonagh S, Phillips J, et al. Angiotensin receptor blocker therapy for heart failure patients: is combination treatment a feasible prospect? Clin Cardiol 2009 Sep; 32 (9): 513-8
210. McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008 May; 1 (1): 17-24
211. Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011 Jan; 13 (1): 107-14
212. Gheorghiade M, Albaghdadi M, Zannad F, et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail 2011 Jan; 13 (1): 100-6
213. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996 May 23; 334 (21): 1349-55 (Pubitemid 26152713)
214. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001 Apr 3; 134 (7): 550-60 (Pubitemid 32245316)
215. No authors listed. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996 Oct 15; 78 (8): 902-7
216. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005 Aug 2; 46 (3): 425-31 (Pubitemid 41040281)
217. Anand IS, Tam SW, Rector TS, et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 2007 Jan 2; 49 (1): 32-9 (Pubitemid 46026903)
218. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006 Jun 15; 97 (12): 1759-64 (Pubitemid 43817867)
219. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007 Oct; 9 (10): 1064-9 (Pubitemid 47451811)
220. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006 Jun; 27 (12): 1431-9 (Pubitemid 43998077)
221. Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. CochraneDatabase SystRev 2012 Feb 15; 2: CD003838
222. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001 Nov; 111 (7): 513-20 (Pubitemid 33052348)
223. Cosin J,Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002 Aug; 4 (4): 507-13
224. Muller K, Gamba G, Jaquet F, et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV: efficacy and quality of life. Eur J Heart Fail 2003 Dec; 5 (6): 793-801 (Pubitemid 38198067)
225. PackerM,Kessler PD, LeeWH. Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation 1987 Jun; 75 (6 Pt 2): V56-64
226. Elkayam U. Calcium channel blockers in heart failure. Cardiology 1998; 89 Suppl. 1: 38-46 (Pubitemid 28101875)
227. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010 Jun; 16 (6): e1-194
228. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensinconverting enzyme inhibitor ramipril. Circulation 2001 Oct 2; 104 (14): 1615-21 (Pubitemid 32947523)
229. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 Dec 4; 359 (23): 2456-67
230. Fu M, Zhou J, Sun A, et al. Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction: a meta analysis of 7 prospective clinical studies. Int J Cardiol 2012 Feb 23; 155 (1): 33-8
231. Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004 Aug 3; 110 (5): 558-65 (Pubitemid 39031173)
232. Treatment Of Preserved Cardiac function heart failure with Aldosterone anTagonist (TOPCAT) [online]. Available from URL: http://www.topcatstudy.com/ index.asp [Accessed 2011 Nov 30]
233. Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009 Jan 13; 53 (2): 184-92
234. Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004 Jun; 6 (4): 453-61 (Pubitemid 38746589)
235. Capomolla S, Febo O, Gnemmi M, et al. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 2000 Apr; 139 (4): 596-608 (Pubitemid 30207784)